Skip to main content

Table 1 Clinicopathologic characteristics by constructed molecular subtype

From: Local-regional control according to surrogate markers of breast cancer subtypes and response to neoadjuvant chemotherapy in breast cancer patients undergoing breast conserving therapy

Characteristic HR+/HER2-
(n= 309)
HR+/HER2+
(n= 51)
HR-/HER2+
(n= 42)
HR-/HER2-
(n= 193)
* P-value
Age, years      0.28
Median
(range)
51
(29 to 83)
51
(27 to 72)
49
(26 to 65)
49
(27 to 76)
 
Clinical T-stage      0.09
T0 1 (0.3%) 0 0 0  
T1 65 (21%) 5 (10%) 6 (14%) 19 (10%)  
T2 207 (67%) 36 (70%) 33 (79%) 140 (73%)  
T3 25 (8%) 5 (10%) 3 (7%) 22 (11%)  
T4 10 (3%) 5 (10%) 0 12 (6%)  
Tx 1 (0.3%) 0 0 0  
Clinical N-stage      0.03
N0 167 (54%) 29 (57%) 11 (26%) 101 (52%)  
N1 110 (36%) 15 (29%) 23 (55%) 62 (32%)  
N2 12 (4%) 1 (2%) 4 (9.5%) 9 (5%)  
N3 20 (6%) 6 (12%) 4 (9.5%) 21 (11%)  
Clinical stage      0.18
I 26 (8%) 4 (8%) 2 (5%) 8 (4%)  
II 234 (76%) 35 (69%) 30 (71%) 137 (71%)  
II 50 (16%) 12 (23%) 10 (24%) 48 (25%)  
Nuclear grade      < 0.001
1 15 (5%) 1 (2%) 0 0  
2 144 (47%) 14 (28%) 3 (7%) 21 (11%)  
3 149 (48%) 36 (70%) 39 (93%) 172 (89%)  
Unknown 1 (0.3%) 0 0 0  
LVI      0.47
Yes 55 (18%) 5 (10%) 7 (17%) 28 (15%)  
No 254 (82%) 46 (90%) 35 (83%) 165 (85%)  
Pathologic tumor size, cm      < 0.001
Median
(range)
1.5
(0 to 9)
1.1
(0 to 4)
0.1
(0 to 8)
0.3
(0 to 5.5)
 
Number positive lymph nodes      
0 152 (49%) 34 (67%) 27 (64%) 149 (77%) < 0.001
1-3 103 (33%) 9 (18%) 11 (26%) 32 (17%)  
≥ 4 53 (17%) 6 (12%) 4 (10%) 12 (6%)  
Unknown 1 (0.3%) 2 (3%) 0 0  
Number lymph nodes sampled      0.04
Median
(range)
12
(0 to 40)
5
(0 to 27)
13
(1 to 37)
9
(1 to 30)
 
pCR      < 0.001
Yes 27 (9%) 9 (18%) 15 (36%) 73 (38%)  
No 282 (91%) 42 (18%) 27 (64%) 120 (62%)  
  1. *The Kruskal-Wallis test was used for age (continuous variable). All other P-values were determined using the χ2 test for equality of distributions. LVI, lymphovascular invasion; pCR, pathologic complete response